OVERVIEW

Podcast: Optimizing Treatment Selection, Sequencing, and Tolerability in Small Cell Lung Cancer is organized by i3 Health.

Dates Available:
November 15, 2022 - November 14, 2023

Statement of Need:
An estimated 236,740 new cases of lung cancer are reported in the United States annually, and 130,180 people die of the disease. Approximately 14% of cases are classified as small cell lung cancer (SCLC). While SCLC is usually treated with systemic therapy with or without radiation, the 5-year relative survival rate is a dismal 7%, indicating a need for continued research on more effective approaches to tumor control (ACS, 2022). To improve outcomes for patients with SCLC, remaining up to date with the latest clinical data in systemic therapy and radiotherapy is key. In this Video Viewpoint Strategy Session, Anne Chiang, MD, PhD, Associate Professor of Medicine, and Henry Park, MD, MPH, Chief of the Thoracic Radiotherapy Program, both at Yale School of Medicine, will examine recent clinical advances and new opportunities in the management of SCLC, and discuss key clinical questions engendered by recent advances in treatment and the need for individualized care.

Learning Objectives:
Upon completion of this activity, participants should be able to

Assess patient-, tumor-, and treatment-related factors that can inform individualized management plans in SCLC
Appraise recent clinical trial data on the safety and efficacy of novel therapies for metastatic SCLC
Evaluate strategies to enhance the safety and tolerability of treatment for SCLC

Faculty:
Anne Chiang, MD, PhD
Associate Professor of Medicine
Chief Network Officer
Deputy Chief Medical Officer
Smilow Cancer Network
Yale School of Medicine

Henry S. Park, MD, MPH
Radiation Oncologist
Associate Professor of Therapeutic Radiology
Vice Chair for Clinical Research
Chief of Thoracic Radiotherapy
Smilow Cancer Network
Yale School of Medicine